WO2009108917A3 - Marqueurs pour la détection améliorée du cancer du sein - Google Patents

Marqueurs pour la détection améliorée du cancer du sein Download PDF

Info

Publication number
WO2009108917A3
WO2009108917A3 PCT/US2009/035654 US2009035654W WO2009108917A3 WO 2009108917 A3 WO2009108917 A3 WO 2009108917A3 US 2009035654 W US2009035654 W US 2009035654W WO 2009108917 A3 WO2009108917 A3 WO 2009108917A3
Authority
WO
WIPO (PCT)
Prior art keywords
breast cancer
identification
markers
genes
improved detection
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2009/035654
Other languages
English (en)
Other versions
WO2009108917A2 (fr
Inventor
James Herman
Nita Ahuja
Kornel E. Scheubel
Leslie Cope
Valerie Deregowski
Wim Van Criekinge
Stephen Baylin
Leander Van Neste
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MDxHealth SA
Johns Hopkins University
Original Assignee
OncoMethylome Sciences SA
Johns Hopkins University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by OncoMethylome Sciences SA, Johns Hopkins University filed Critical OncoMethylome Sciences SA
Publication of WO2009108917A2 publication Critical patent/WO2009108917A2/fr
Publication of WO2009108917A3 publication Critical patent/WO2009108917A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/154—Methylation markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Plusieurs gènes sont identifiés comme présentant une méthylation différentielle dans le cancer du sein. Cette information est utile pour le dépistage, l’évaluation de risque, le pronostic du cancer du sein, l’identification de la maladie, la stadification de la maladie, et l’identification de cibles thérapeutiques. L’identification de gènes qui sont méthylés dans le cancer du sein permet des dosages pour le diagnostic précoce précis et efficaces, l’établissement de profil de méthylation au moyen d’une pluralité de gènes et l’identification de nouvelles cibles pour une intervention thérapeutique.
PCT/US2009/035654 2008-02-29 2009-03-02 Marqueurs pour la détection améliorée du cancer du sein Ceased WO2009108917A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3258308P 2008-02-29 2008-02-29
US61/032,583 2008-02-29

Publications (2)

Publication Number Publication Date
WO2009108917A2 WO2009108917A2 (fr) 2009-09-03
WO2009108917A3 true WO2009108917A3 (fr) 2010-07-01

Family

ID=41016742

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/035654 Ceased WO2009108917A2 (fr) 2008-02-29 2009-03-02 Marqueurs pour la détection améliorée du cancer du sein

Country Status (1)

Country Link
WO (1) WO2009108917A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107988366A (zh) * 2017-12-22 2018-05-04 深圳市宝安区妇幼保健院 一种用于诊断评估乳腺癌的试剂盒、甲基化hoxa4/dpp6基因的检测及其应用

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2755734A1 (fr) * 2009-03-17 2010-09-23 Gaetan Otto Detection amelioree de l'expression de genes
EP2603796B1 (fr) 2010-08-13 2016-05-25 Arizona Board of Regents, a body corporate acting on behalf of Arizona State University Biomarqueurs pour la détection précoce du cancer du sein
SG11201400269YA (en) * 2011-08-30 2014-09-26 Dcb Usa Llc Gene biomarkers for prediction of susceptibility of ovarian neoplasms and/or prognosis or malignancy of ovarian cancers
WO2013043128A1 (fr) 2011-09-20 2013-03-28 Brigham And Women's Hospital Sall4 et utilisations de ce gène
US10378060B2 (en) 2011-10-14 2019-08-13 Dana-Farber Cancer Institute, Inc. ZNF365/ZFP365 biomarker predictive of anti-cancer response
US9090944B2 (en) * 2011-12-16 2015-07-28 The Chinese University Of Hong Kong Biomarker DACT1 for gastric cancer
AU2013276226A1 (en) * 2012-06-13 2015-02-05 King Abdullah University Of Science And Technology Methylation biomarkers for breast cancer
US11697674B2 (en) 2017-10-16 2023-07-11 Institute For Cancer Research Human chorionic gonadotropin variant peptides and treatment of breast cancer
CA3096668A1 (fr) * 2018-04-12 2019-10-17 Singlera Genomics, Inc. Compositions et methodes d'evaluation et de traitement d'un cancer ou d'une neoplasie
WO2020019268A1 (fr) * 2018-07-26 2020-01-30 北京艾克伦医疗科技有限公司 Méthode pour identifier l'état d'un cancer du sein et kit
US20220267858A1 (en) * 2019-07-19 2022-08-25 Vinius University Characterization of prostate cancer using dna methylation assay system
CN117305461A (zh) * 2019-12-31 2023-12-29 上海奕谱生物科技有限公司 新型的诊断肿瘤的标志物及其应用
CN111899789B (zh) * 2020-08-03 2021-05-25 北京市肿瘤防治研究所 二代测序鉴定brca1/2大片段重排的方法及系统
WO2022125417A1 (fr) * 2020-12-07 2022-06-16 Institute For Cancer Research D/B/A The Research Institute Of Fox Chase Cancer Center Traitement de femelles ayant des mutations brca1/2 avec de la gonadotrophine chorionique humaine pour réduire le risque de développer un cancer du sein
WO2023082141A1 (fr) * 2021-11-11 2023-05-19 华大数极生物科技(深圳)有限公司 Marqueur de méthylation hist1h3g pour la détection du cancer hépatique
CN114480655B (zh) * 2022-03-03 2024-07-16 北京起源聚禾生物科技有限公司 Dna甲基化标志物组合及应用、卵巢癌早期检测引物探针及试剂盒
CN114959038B (zh) * 2022-06-13 2024-12-17 湖南宏雅基因技术有限公司 一种hoxa9基因甲基化检测试剂及其应用
WO2024006577A1 (fr) * 2022-07-01 2024-01-04 Ohio State Innovation Foundation Procédés et compositions pour identifier des signatures de gène hox afin d'affecter des thérapies spécifiques et efficaces dans la leucémie myéloïde aiguë et d'autres cancers
CN116064771B (zh) * 2022-09-27 2026-03-20 中山大学 一种促进细胞铁死亡的基因的功能确定及应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030143606A1 (en) * 2000-06-30 2003-07-31 Alexander Olek Diagnosis of diseases associated with the immune system by determining cytosine methylation
US20030186277A1 (en) * 2000-06-30 2003-10-02 Alexander Olek Diagnosis of known genetic parameters within the mhc
US20040234960A1 (en) * 2000-09-01 2004-11-25 Alexander Olek Method for determining the degree of methylation of defined cytosines in genomic dna in the sequence context 5'-cpg-3'
US20060051768A1 (en) * 2003-03-25 2006-03-09 John Wayne Cancer Institute DNA markers for management of cancer

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030143606A1 (en) * 2000-06-30 2003-07-31 Alexander Olek Diagnosis of diseases associated with the immune system by determining cytosine methylation
US20030186277A1 (en) * 2000-06-30 2003-10-02 Alexander Olek Diagnosis of known genetic parameters within the mhc
US20040234960A1 (en) * 2000-09-01 2004-11-25 Alexander Olek Method for determining the degree of methylation of defined cytosines in genomic dna in the sequence context 5'-cpg-3'
US20060051768A1 (en) * 2003-03-25 2006-03-09 John Wayne Cancer Institute DNA markers for management of cancer

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
SCHUEBEL ET AL.: "Comparing the DNA hypermethylome with gene mutations in human colorectal cancer.", PLOS GENETICS, vol. 3, no. 9, 2007, pages 1709 - 1723 *
YAMASHITA ET AL.: "GP9.5 methylation in diffuse-type gastric cancer.", CANCER RESEARCH, vol. 66, no. 7, 2006, pages 3921 - 3927 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107988366A (zh) * 2017-12-22 2018-05-04 深圳市宝安区妇幼保健院 一种用于诊断评估乳腺癌的试剂盒、甲基化hoxa4/dpp6基因的检测及其应用
CN107988366B (zh) * 2017-12-22 2020-07-14 深圳市宝安区妇幼保健院 一种用于诊断评估乳腺癌的试剂盒、甲基化hoxa4/dpp6基因的检测及其应用

Also Published As

Publication number Publication date
WO2009108917A2 (fr) 2009-09-03

Similar Documents

Publication Publication Date Title
WO2009108917A3 (fr) Marqueurs pour la détection améliorée du cancer du sein
WO2008107134A3 (fr) Procédé de détection d'un cancer du foie, d'un risque de cancer du foie, d'un risque de récidive de cancer du foie, de la malignité d'un cancer du foie et de la progression d'un cancer du foie dans le temps en utilisant la cytosine méthylée dans le gène basp1a et/ou le gène s
Tan et al. Potential biomarkers for esophageal cancer
WO2010125566A3 (fr) Marqueurs pour la détection d'un cancer
EP2611941A4 (fr) Signatures génétiques pour le diagnostic et le pronostic du cancer
WO2007095644A3 (fr) reactifs et procedes pour le pronostic et la stadification pathologique d'un cancer
WO2009019368A3 (fr) Procede de dosage de la liver fatty acid-binding protein, de l'ace et du ca19-9 pour le diagnostic in vitro du cancer colorectal
BR112015004423A8 (pt) método iii de rastreamento de câncer, métodos de rastreamento de câncer do colo do útero, do ovário, do fígado, do cólon, de mama, oral e do endométrio e método de rastreamento de sarcoma
MX2018011725A (es) Metodo para emplear expresion genica para determinar pronostico de cancer de prostata.
WO2009002931A3 (fr) Procédés et utilisations de prosaposine
IL202371A0 (en) Multigene prognostic assay for lung cancer
WO2009024691A3 (fr) Procede de dosage du leucocyte elastase inhibitor pour le diagnostic in vitro du cancer colorectal
WO2013057581A3 (fr) Biomarqueurs composites pour criblage, diagnostic et pronostic non invasifs de cancer colorectal
WO2008154098A3 (fr) Réactifs et procédés permettant une analyse d'expression d'arnmi et identification de biomarqueurs de cancer
Hwang et al. Identification of FOXM1‐induced epigenetic markers for head and neck squamous cell carcinomas
WO2009019370A3 (fr) Procede de dosage de l'apolipoproteine aii pour le diagnostic in vitro du cancer colorectal
WO2009019367A3 (fr) Procede de dosage de l'apolipoproteine ai pour le diagnostic in vitro du cancer colorectal
WO2007120362A3 (fr) Adenovirus adipogenes comme biomarqueur d'une maladie
WO2008037700A3 (fr) Procédés pour pronostiquer un cancer du sein
UY36200A (es) Conjunto de biomarcadores específicos para diagnóstico no invasivo de cáncer de hígado
WO2009074328A3 (fr) Methodes et acides nucleiques permettant d'analyser les troubles de la proliferation cellulaire
WO2012129488A3 (fr) Signatures géniques associées au rejet ou à la récurrence du cancer
MX2021010086A (es) Panel de biomarcadores para el diagnostico y el pronostico del cancer.
WO2006133923A3 (fr) Diagnostic, pronostic, et prediction de la recurrence des cancers du sein
WO2009019369A3 (fr) Procede de dosage de la plastine-i pour le diagnostic in vitro du cancer colorectal

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09714106

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09714106

Country of ref document: EP

Kind code of ref document: A2